Leukos Biotech

Leukos Biotech is a biopharmaceutical company focused on the development of new treatments for Acute Myeloid Leukaemia and other haematological malignancies. The company was founded in 2015 as a spin-off from the Josep Carreras Leukaemia Research Institute (IJC) and has a strong scientific, institutional and economic support from the IJC and the Josep Carreras Leukaemia Foundation, among other partners and collaborators. The company has closed a licensing agreement with the Austrian pharmaceutical company AOP-Health to develop LB208, the first clinical candidate, in oncological indications starting with haematological tumors. Leukos, together with VHIR and Leitat, received in November 2022 a 1,4M€ grant/loan (CPP2021-008715) investigate further the mechanism of action of LB208, a tumor-specific oral HTR1B antagonist, and to perform an exploratory clinical trial